Zobrazeno 1 - 10
of 109
pro vyhledávání: '"G.R. Peters"'
Autor:
NÁDIA F. GARCIA, CAMILA DE MORAES, MACÁRIO A. REBELO, SAVANAH MARIA G.R. PETERS, FÁBIO M.P. DE CASTRO, ENRICO F. PUGGINA
Publikováno v:
Anais da Academia Brasileira de Ciências, Vol 94, Iss suppl 3 (2022)
Abstract Strength training (ST) with blood flow restriction (BFR) is known to promote increases in hypertrophy and strength sometimes similar to traditional ST despite the effects of the arterial BFR on muscle adaptations and safety are not well esta
Externí odkaz:
https://doaj.org/article/269e03ec1f6c4f82b0d111211dc094e4
Publikováno v:
European Journal of Clinical Pharmacology. 50:139-145
Objective: Tirilazad mesylate is a membrane lipid peroxidation inhibitor being evaluated for the treatment of patients with subarachnoid haemorrhage (SAH); phenobarbital may be administered to these patients for seizure prophylaxis. Therefore, the ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df859c88d0772bb4cfae575a7d99fe05
https://doi.org/10.1007/s002280050082
https://doi.org/10.1007/s002280050082
Publikováno v:
Human Psychopharmacology: Clinical and Experimental. 10:97-104
The effect on digit-symbol substitution (DSST) of duration and extent of exposure to midazolam was studied in seven healthy male volunteers. Individual pharmacokinetic and pharmacodynamic parameters were estimated after a 7·5 mg intravenous bolus do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3856aa3eb74bb8426f1e4e3d31b15626
https://doi.org/10.1002/hup.470100204
https://doi.org/10.1002/hup.470100204
Publikováno v:
Clinical Pharmacology and Therapeutics. 56:389-397
The pharmacokinetic interaction between phenytoin and tirilazad was studied in 12 healthy men who received 200 mg phenytoin orally every 8 hours for 11 doses and 100 mg for the remaining 5 doses in one period of a two-way crossover study. In both per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b104701cb71e0b925a98d284cefa57
https://doi.org/10.1038/clpt.1994.153
https://doi.org/10.1038/clpt.1994.153
Publikováno v:
The Journal of Clinical Pharmacology. 34:837-841
The potential interaction between tirilazad mesylate, a membrane lipid peroxidation inhibitor, and nimodipine, a calcium-channel antagonist, was assessed in 12 healthy male volunteers. Subjects received 60 mg nimodipine orally, 2.0 mg/kg tirilazad me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2563ff0d6d25d05a7ba41a54a9642c53
https://doi.org/10.1002/j.1552-4604.1994.tb02048.x
https://doi.org/10.1002/j.1552-4604.1994.tb02048.x
Autor:
John D Harry, Joseph C. Fleishaker, G.R. Peters, Penelope Ward, D Mark Wright, Laura K. Hulst
Publikováno v:
Clinical Pharmacology and Therapeutics. 55:378-384
Tirilazad mesylate pharmacokinetics were assessed in 12 young and 12 elderly volunteers (six men and six women per age group). Subjects received single 10-minute intravenous infusions of 1.5 mg/kg and 3.0 mg/kg tirilazad mesylate. Plasma tirilazad me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::818138d8608792196ddcb4e3547846fc
https://doi.org/10.1038/clpt.1994.45
https://doi.org/10.1038/clpt.1994.45
Publikováno v:
Pharmaceutical Research. 11:341-344
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32a087bdda128fb31700bd0673fb9b74
https://doi.org/10.1023/a:1018988331700
https://doi.org/10.1023/a:1018988331700
Publikováno v:
Journal of clinical pharmacology. 37(6)
Pramipexole is a dopamine receptor agonist that has proved effective in the treatment of Parkinson's disease. The pharmacokinetic properties of pramipexole at steady-state concentrations were studied in 16 healthy men and women at four dose levels th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045fa168eee93ca3c6498f48d0b7a034
https://pubmed.ncbi.nlm.nih.gov/9208359
https://pubmed.ncbi.nlm.nih.gov/9208359
Publikováno v:
European journal of clinical pharmacology. 50(4)
The pharmacokinetics of tirilazad mesylate and an active reduced metabolite, U89678, were studied in 7 volunteers with mild cirrhosis of the liver, and seven age, sex, weight and smoking status matched healthy normal volunteers. Subjects received a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bddb14c76aa3e08e1e13ab68bed871c0
https://pubmed.ncbi.nlm.nih.gov/8803523
https://pubmed.ncbi.nlm.nih.gov/8803523
Publikováno v:
American journal of therapeutics. 2(8)
The pharmacokinetics of tirilazad were assessed in men ages 40--60 years, women
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d75341701a1178d6be28d4d83c73de
https://pubmed.ncbi.nlm.nih.gov/11854826
https://pubmed.ncbi.nlm.nih.gov/11854826